RNS Number : 1014E
DeepMatter Group PLC
26 October 2022
 

Text Description automatically generated                                                                                                                                                

26 October 2022

 

DeepMatter signs multi-year license agreement with the Life Science business sector of Merck

 

DeepMatter Group Plc (AIM: DMTR, "Deepmatter", the "Group"), the digital chemistry data and software company, has signed a multiyear database license agreement with Merck, a leading science and technology company, operating across Healthcare, Life Science and Electronics.

 

Pursuant to the agreement, DeepMatter will licence to the Life Science business sector of Merck certain proprietary data for machine learning-based applications. The terms of the agreement were not disclosed.

 

"We are delighted to announce an important licensing agreement with Merck, one of the leading companies using digitalisation in healthcare and life sciences to deliver our vision to provide the data that enables all medicines to be made in the best possible way," said Mark Warne, CEO of DeepMatter.

 

Merck and Deepmatter will also explore ways to identify, acquire, generate and structure sets of chemical reaction data that can be used to enable scientists to develop new molecules faster and more efficiently which could encompass use of DeepMatter's SmartChemistry® capabilities.

 

For more information contact

 

DeepMatter Group Plc
Mark Warne, Chief Executive Officer                                                                                      0141 548 8156

Fraser Benson, Chief Financial Officer                                                                                    

                                                                               
Canaccord Genuity Limited (Nominated Adviser and Broker)                                    
Bobbie Hilliam                                                                                                                                   020 7523 8000


Meare Consulting                                                                                                                      
 Adrian Duffield                                                                                                                                 07990 858548

                 

About DeepMatter Group plc 

 

DeepMatter's SmartChemistry® platform enables scientists across a range of industries, including pharma, biotech, agri-science, scientific publishers and contract research organisations (CROs), to easily capture, access and exploit the vast amounts of data created in chemical reactions.  

 

DeepMatter integrates its proprietary chemistry data and proprietary software to significantly improve productivity, efficiency, discovery, safety and sustainability of chemical reactions for its customers.

 

DeepMatter's SmartChemistry® platform capitalises on the combination of its cloud technology, low cost-sensors, connectivity to laboratory hardware and high-performance computing trends such as artificial intelligence (AI).

 

Visit: www.deepmatter.io and follow @deepmattergroup

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
AGRFELLLLBLEFBL